Altis Biosystems has created a next-generation in vitro platform that reduces the time and cost of developing safer, more effective drugs.
By replicating native human biology, the intestinal stem cell platform produces more accurate and reproducible data for better clinical trial performance and reduces the need for animal testing.
The RepliGut® Platform
RepliGut® is a unique, stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.
With a scalable platform, actionable data, high throughput screening to test thousands of compounds, and an unrivaled biobank, RepliGut® is the future of in vitro testing during drug development.
The RepliGut® is a reproducible and scalable platform that is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.
NEWS AND ARTICLES
August 5, 2021
The Power Of RepliGut® In Vitro Intestinal Stem Cell Models
Both current in vitro and in vivo models used in the development of candidate therapies for the treatment of intestinal diseases have severe limitations. RepliGut®, an in vitro human intestinal epithelial stem cell model, addresses many of these issues and has significant potential to reduce the time and cost of drug development. This model may even help to identify optimal therapies for individual patients.Read More
April 12, 2021
Developing A Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity
Gastrointestinal (GI) issues are common side effects of many drugs. Anticipating such side effects before clinical trials is limited by a lack of effective models for evaluating preclinical candidates for their potential to cause diarrhea, nausea, and other gut-related side effects. With its RepliGut® in vitro human intestinal model, Altis Biosystems is developing a system that could help pharma companies identify GI toxicity issues early in the drug development process.Read More
November 17-28, 2021
Microbiome Connect: Gut Therapeutics
Have a question? Want to stay informed about Altis, RepliGut, and more platforms currently under development? Send us a message!